185 related articles for article (PubMed ID: 26656134)
41. Role of Intrapancreatic SPINK1/Spink3 Expression in the Development of Pancreatitis.
Ohmuraya M; Sugano A; Hirota M; Takaoka Y; Yamamura K
Front Physiol; 2012; 3():126. PubMed ID: 22586407
[TBL] [Abstract][Full Text] [Related]
42. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
[TBL] [Abstract][Full Text] [Related]
43. Mutations N34S and P55S of the SPINK1 gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects: a report from Finland.
Lempinen M; Paju A; Kemppainen E; Smura T; Kylänpää ML; Nevanlinna H; Stenman J; Stenman UH
Scand J Gastroenterol; 2005 Feb; 40(2):225-30. PubMed ID: 15764155
[TBL] [Abstract][Full Text] [Related]
44. [SPINK1 N34S mutation as a possible cause of chronic pancreatitis in a patient with familial background].
Oh HC; Lee TY; Kwon S; Lee SS; Seo DW; Lee SK; Kim MH
Korean J Gastroenterol; 2007 Jun; 49(6):384-9. PubMed ID: 17641557
[TBL] [Abstract][Full Text] [Related]
45. Biomarker development, from bench to bedside.
Stenman UH
Crit Rev Clin Lab Sci; 2016; 53(2):69-86. PubMed ID: 26287282
[TBL] [Abstract][Full Text] [Related]
46. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
[TBL] [Abstract][Full Text] [Related]
47. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
48. [Hereditary aspects of pancreatitis].
Bak D; Sobczyńska-Tomaszewska A; Bal J
Med Wieku Rozwoj; 2003; 7(1):57-66. PubMed ID: 13130170
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
50. SPINK1/PSTI mutations are associated with tropical pancreatitis in Bangladesh. A preliminary report.
Rossi L; Pfützer RH; Parvin S; Ali L; Sattar S; Kahn AK; Gyr N; Whitcomb DC
Pancreatology; 2001; 1(3):242-5. PubMed ID: 12120202
[TBL] [Abstract][Full Text] [Related]
51. Missense mutations in pancreatic secretory trypsin inhibitor (SPINK1) cause intracellular retention and degradation.
Király O; Wartmann T; Sahin-Tóth M
Gut; 2007 Oct; 56(10):1433-8. PubMed ID: 17525091
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
53. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
54. Motion--genetic testing is useful in the diagnosis of nonhereditary pancreatic conditions: arguments for the motion.
Whitcomb DC
Can J Gastroenterol; 2003 Jan; 17(1):47-52. PubMed ID: 12560855
[TBL] [Abstract][Full Text] [Related]
55. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization.
Suwa T; Kobayashi M; Shirai Y; Nam JM; Tabuchi Y; Takeda N; Akamatsu S; Ogawa O; Mizowaki T; Hammond EM; Harada H
JCI Insight; 2021 Nov; 6(21):. PubMed ID: 34747365
[TBL] [Abstract][Full Text] [Related]
56. Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients.
Piepoli A; Gentile A; Valvano MR; Barana D; Oliani C; Cotugno R; Quitadamo M; Andriulli A; Perri F
World J Gastroenterol; 2006 Oct; 12(39):6343-8. PubMed ID: 17072959
[TBL] [Abstract][Full Text] [Related]
57. Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice.
Ohmuraya M; Hirota M; Araki M; Mizushima N; Matsui M; Mizumoto T; Haruna K; Kume S; Takeya M; Ogawa M; Araki K; Yamamura K
Gastroenterology; 2005 Aug; 129(2):696-705. PubMed ID: 16083722
[TBL] [Abstract][Full Text] [Related]
58. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
59. Association of rare SPINK1 gene mutation with another base substitution in chronic pancreatitis patients.
Kalinin VN; Kaifi JT; Schwarzenbach H; Sergeyev AS; Link BC; Bogoevski D; Vashist Y; Izbicki JR; Yekebas EF
World J Gastroenterol; 2006 Sep; 12(33):5352-6. PubMed ID: 16981266
[TBL] [Abstract][Full Text] [Related]
60. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
